DarkMatter2BD: Jim Manousos Chief Co-founder, Data Scientist and Vincent DeChellis Co-founder, Principal

JIM PLEASE TELL OUR READERS A LITTLE ABOUT YOURSELF

I've spent my career managing data  and technology across a spectrum of life sciences activities including product launches, operation & operations research, clinical trials, marketing, data warehouse modeling and master database management (MDM) solutions. Prior to co-founding DarkMatter2bd with my partner Vince DeChellis, I started two analytics companies. I'm often credited with the redesign and construction of the largest medical claims repository still available, including the initial projection methodology and matching algorithms for tracking blinded patient claims on a daily basis. 

THANKS JIM. VINCE I BELIEVE YOU HAVE A BACKGROUND IN STRATEGIC PLANNING IS THAT CORRECT? 

That's right. I specialize in pharmaceutical marketing and health information technology focused on strategic planning and analytics in the Life Sciences industry. I was the principal and founder of NHHS Healthcare Consulting in 2005 and subsequently co-founded DarkMatter2bd with Jim in 2012. I focused DarkMatter2BD on the rapidly growing opportunities in health information technology, business intelligence and database development/analytics. Our MedFuse Database has brought a valuable new resource to life sciences R&D and marketing. 

WHAT MAKES DARKMATTER2BD UNIQUE?

We provide refined real world data, planning and resources to the life science and healthcare industry powered by a proprietary database, MedFuse™. A cloud based business intelligence (BI) and customer management platform it enables rapid decision-making and end user access to a wide range of targeting and clinical applications for R&D, marketing and sales.

Data dimensions include: 

  • Patient density analysis nationally down to zip code & provider
  • ICD-9 Diagnosis and treatment
  • Breakouts: Age, Gender, Location
  • Patient and Provider counts
  • Referral patterns
  • High density practices - find concentrations of eligible patients and providers with extensive experience treating targeted disease states
  • BI visualization interface creates regional and nationwide maps depicting exactly where every patient, provider, practice and facility are located
  • Provider networks regarding affiliations and relationship 

DarkMatter is also connected to social media and EHR partners to extend networking services into a rapidly growing HIT provider communications ecosystem. 

WHAT'S NEW AND EXCITING AT DARKMATTER2BD?

We've built a compelling cloud-based Big Data solution, which combines over 2 trillion records and 20 billion rows of clinical data. My partner Vince DeChellis showed at DIA last year what the media has been describing as a potential game changer in the clinical space. Many companies having been using Big Data to find relationships between physicians, patients, and products. But we are focused on taking this to the next level at scale to include meaningful relationships existing between physicians. 

Accurate and up-to-date affiliations between HCPs and HCOs have always been a challenge for life sciences companies. When DarkMatter2BD is integrated into Reltio’s data-as-a-service it opens up a wealth of possibilities with data-driven applications to more efficiently manage important thought leaders.

HOW DO YOU SEE CUSTOMERS BENEFITING FROM THE COMBINATION OF DARKMATTER2BD AND RELTIO?

As more companies seek to make faster and better use of their data assets Reltio offers an enterprise cloud based data-driven application and modern data management solution to help companies manage their data assets and turn them into actionable information. Our joint customers can take delivery of DarkMatter data and combine it with enterprise data resulting in a platform of continually enhanced customer and account information. Reltio potentiates the value of DarkMatter data for life sciences companies by providing an efficient integration destination, and delivering it straight to frontline business users through data-driven applications.